Amended Report of Foreign Issuer (6-k/a)
June 23 2017 - 4:08PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
(Amendment No. 1)
Report of Foreign Private Issuer Pursuant
to Rule 13a-16 or 15d-16
Under the Securities Exchange Act of 1934
For the Month of June 2017
001-36345
(Commission File Number)
GALMED PHARMACEUTICALS LTD.
(Exact name of Registrant as specified in
its charter)
16 Tiomkin St.
Tel Aviv 6578317, Israel
(Address of principal executive offices)
Indicate by check mark whether the registrant
files or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F
x
Form 40-F
¨
Indicate by check mark if the registrant
is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____
Indicate by check mark if the registrant
is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____
EXPLANATORY NOTE
Galmed Pharmaceuticals Ltd. (the “Company”)
is filing this Amendment No. 1 to the Company’s Form 6-K (this “Amendment”) to file Exhibit 101, which was inadvertently
not included in the original Form 6-K filed with the Securities and Exchange Commission on August 3, 2016 (the “Original
Form 6-K”) and attached herein as an exhibit to this Amendment. Exhibit 101 provides the financial statements included in
the Original Form 6-K formatted in XBRL (eXtensible Business Reporting Language).
This Amendment speaks
as of the filing date of the Original Form 6-K, does not reflect events that have occurred after the filing date of the Original
Form 6-K, and does not amend, modify or update in any way disclosures made in the Original Form 6-K except as set forth in this
explanatory note.
This Amendment and
the Original Form 6-K are incorporated by reference into the Company's Registration Statement on Form S-8 (Registration No. 333-206292)
and its Registration Statement on Form F-3 (Registration No. 333- 203133).
EXHIBIT INDEX
Exhibit No.
|
|
Description
|
|
|
|
101.INS
|
|
XBRL
Instance Document
|
|
|
|
101.SCH
|
|
XBRL
Taxonomy Extension Schema Document
|
|
|
|
101.CAL
|
|
XBRL Taxonomy Extension
Calculation Linkbase Document
|
|
|
|
101.DEF
|
|
XBRL Taxonomy Extension
Definition Linkbase Document
|
|
|
|
101.LAB
|
|
XBRL
Taxonomy Extension Label Linkbase Document
|
|
|
|
101.PRE
|
|
XBRL Taxonomy Extension
Presentation Document
|
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized.
|
Galmed Pharmaceuticals Ltd.
|
|
|
|
Date: June 23, 2017
|
By:
|
/s/ Allen Baharaff
|
|
|
Allen Baharaff
|
|
|
President and Chief Executive Officer
|
Galmed Pharmaceuticals (NASDAQ:GLMD)
Historical Stock Chart
From Aug 2024 to Sep 2024
Galmed Pharmaceuticals (NASDAQ:GLMD)
Historical Stock Chart
From Sep 2023 to Sep 2024